Publication date: May 21, 2026
Background: The Vaccine Safety Datalink (VSD) detected a statistical signal for ischemic events (ischemic stroke or transient ischemic attack) following bivalent mRNA COVID-19 vaccination through prospective surveillance during 2022-2023. Although multiple studies from other surveillance systems and countries reported no increased risk, important methodological limitations remained. This U.S. study addressed those limitations by evaluating the ischemic stroke risk following bivalent mRNA COVID-19 vaccination, influenza vaccination, and their same-day coadministration using event-dependent self-controlled case series (SCCS) design. Methods: Study outcomes included first-ever ischemic stroke (primary outcome), first-in-1-year ischemic stroke (secondary outcome), and ischemic events (exploratory outcomes), identified using ICD-10-CM codes in inpatient and emergency department settings during September 1, 2022-March 31, 2023, among individuals aged>=12 years across eight VSD sites. Analyses were conducted separately for Pfizer-BioNTech and Moderna bivalent vaccines, with relative incidences (RI) and 95% confidence intervals (CI) estimated for 1-21-day and 1-42-day risk intervals, using person-time outside these intervals as the control period. Subgroup analyses were performed by age group (12-64, >65 years) and history of documented SARS-CoV-2 infection. Results: A total of 6,510 first-ever ischemic strokes were identified among more than 6.8 million participants. Among recipients of Pfizer-BioNTech bivalent COVID-19 and influenza vaccines, no statistically significant increased risk of first-ever ischemic stroke was observed following bivalent COVID-19 vaccination (RI=0.94; 95% CI: 0.63-1.41), influenza vaccination (RI=0.95; 95% CI: 0.82-1.10), or same-day coadministration (RI=1.15; 95% CI: 0.88-1.49) within 1-21-day risk intervals; findings were similar for 1-42-day intervals. Comparable null results were observed for Moderna vaccines and across all subgroups, secondary, and exploratory outcomes. Conclusion: No increased risk of ischemic stroke was found following bivalent mRNA COVID-19 vaccination, influenza vaccination, or their coadministration in this multi-site SCCS study. These findings are consistent with previous studies and underscore the importance of continued vaccine safety monitoring.
| Concepts | Keywords |
|---|---|
| 2022march | Bivalent |
| Glaxosmithkline | Coadministration |
| Influenza | Covid |
| Seattle | Day |
| Tutorial | Events |
| Influenza | |
| Intervals | |
| Ischemic | |
| Preprint | |
| Risk | |
| Stroke | |
| Vaccination | |
| Vaccine | |
| Vaccines | |
| Years |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Ischemic stroke |
| disease | MESH | COVID-19 |
| disease | MESH | influenza |
| disease | MESH | transient ischemic attack |
| disease | MESH | included |
| disease | MESH | ICD |
| disease | MESH | emergency |
| pathway | REACTOME | SARS-CoV-2 Infection |
| drug | DRUGBANK | Methylphenidate |
| disease | MESH | MHS |
| drug | DRUGBANK | Etodolac |
| disease | MESH | hemorrhagic stroke |
| disease | MESH | myocardial infarction |
| disease | MESH | pulmonary embolism |
| disease | MESH | stroke |
| disease | MESH | death |
| disease | MESH | infection |
| drug | DRUGBANK | Alteplase |
| disease | MESH | headache |
| disease | MESH | dizziness |
| disease | MESH | hemiplegia |
| disease | MESH | sudden visual loss |
| disease | MESH | LSS |
| disease | MESH | MES |
| disease | MESH | Dis |
| disease | MESH | CRC |
| disease | MESH | pds |